enGene (NASDAQ:ENGN – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Morgan Stanley in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $40.00 price target on the stock.
Separately, Oppenheimer began coverage on enGene in a report on Wednesday, August 28th. They set an “outperform” rating and a $30.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $33.67.
Read Our Latest Stock Report on ENGN
enGene Price Performance
enGene (NASDAQ:ENGN – Get Free Report) last posted its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. As a group, equities analysts expect that enGene will post -1.49 earnings per share for the current fiscal year.
Institutional Trading of enGene
Several institutional investors have recently made changes to their positions in ENGN. BVF Inc. IL purchased a new stake in shares of enGene during the 4th quarter valued at approximately $20,777,000. Omega Fund Management LLC purchased a new stake in shares of enGene during the 4th quarter valued at approximately $10,441,000. Janus Henderson Group PLC purchased a new stake in shares of enGene during the 1st quarter valued at approximately $17,095,000. SR One Capital Management LP purchased a new stake in shares of enGene during the 2nd quarter valued at approximately $4,715,000. Finally, Logos Global Management LP raised its position in shares of enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the period. Hedge funds and other institutional investors own 64.16% of the company’s stock.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Stories
- Five stocks we like better than enGene
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Leveraged ETFs to Multiply Returns
- Compound Interest and Why It Matters When Investing
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What is a support level?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.